🚀 VC round data is live in beta, check it out!
Jeol Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jeol and similar public comparables like Draegerwerk, Beijing Balance Medical, Artivion, BoneSupport and more.
Jeol Overview
About Jeol
Jeol Ltd is engaged in the manufacture and sale of scientific and measuring instruments, industrial equipment, and medical equipment. The group has three reportable segments: Scientific and Measuring Instruments, Industrial Equipment, and Medical Equipment. The Scientific and Measuring Instruments segment manufactures and sells electron microscopes, nuclear magnetic resonance devices, and mass spectrometers. The Industrial Equipment segment manufactures and sells electron beam lithography equipment, electron beam metal 3D printers, and high-frequency power supplies. The Medical Equipment segment manufactures and sells automatic analyzers and related products. It generates the majority of its revenue from the Scientific and Measuring Instruments segment.
Founded
1949
HQ
Employees
3.6K
Website
Financials (LTM)
EV
$2B
Jeol Financials
Jeol reported last 12-month revenue of $1B and EBITDA of $196M.
In the same LTM period, Jeol generated $196M in EBITDA and $124M in net income.
Revenue (LTM)
Jeol P&L
In the most recent fiscal year, Jeol reported revenue of $1B and EBITDA of $278M.
Jeol expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $582M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $196M | XXX | $278M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $124M | XXX | $128M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 10% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jeol Stock Performance
Jeol has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Jeol's stock price is $38.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.3% | XXX | XXX | XXX | $2.63 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJeol Valuation Multiples
Jeol trades at 1.5x EV/Revenue multiple, and 8.7x EV/EBITDA.
EV / Revenue (LTM)
Jeol Financial Valuation Multiples
As of April 20, 2026, Jeol has market cap of $2B and EV of $2B.
Equity research analysts estimate Jeol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jeol has a P/E ratio of 15.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | 10.5x | XXX | 7.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.9x | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 14.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jeol Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jeol Margins & Growth Rates
Jeol's revenue in the last 12 month declined by (2%).
Jeol's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Jeol's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jeol's rule of X is 11% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jeol Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (2%) | XXX | (14%) | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | (30%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jeol Public Comps
See public comps and valuation multiples for other Medical Devices and Test & Measurement comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jeol | XXX | XXX | XXX | XXX | XXX | XXX |
| Draegerwerk | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Balance Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Artivion | XXX | XXX | XXX | XXX | XXX | XXX |
| BoneSupport | XXX | XXX | XXX | XXX | XXX | XXX |
| Chengdu RML Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jeol M&A Activity
Jeol acquired XXX companies to date.
Last acquisition by Jeol was on XXXXXXXX, XXXXX. Jeol acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jeol
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJeol Investment Activity
Jeol invested in XXX companies to date.
Jeol made its latest investment on XXXXXXXX, XXXXX. Jeol invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jeol
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jeol
| When was Jeol founded? | Jeol was founded in 1949. |
| Where is Jeol headquartered? | Jeol is headquartered in Japan. |
| How many employees does Jeol have? | As of today, Jeol has over 3K employees. |
| Who is the CEO of Jeol? | Jeol's CEO is Izumi Oi. |
| Is Jeol publicly listed? | Yes, Jeol is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Jeol? | Jeol trades under 6951 ticker. |
| When did Jeol go public? | Jeol went public in 1962. |
| Who are competitors of Jeol? | Jeol main competitors are Draegerwerk, Beijing Balance Medical, Artivion, BoneSupport. |
| What is the current market cap of Jeol? | Jeol's current market cap is $2B. |
| What is the current revenue of Jeol? | Jeol's last 12 months revenue is $1B. |
| What is the current revenue growth of Jeol? | Jeol revenue growth (NTM/LTM) is (2%). |
| What is the current EV/Revenue multiple of Jeol? | Current revenue multiple of Jeol is 1.5x. |
| Is Jeol profitable? | Yes, Jeol is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jeol? | Jeol's last 12 months EBITDA is $196M. |
| What is Jeol's EBITDA margin? | Jeol's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Jeol? | Current EBITDA multiple of Jeol is 8.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.